Cargando…

Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma

The difference in clinical features and treatment outcomes between localized sinonasal diffuse large B cell lymphoma (SN-DLBCL) and sinonasal extranodal NK/T cell lymphoma (SN-ENKTL) is unclear. Therefore, we analyzed a total of 47 patients with localized SN-DLBCL and 211 patients with localized SN-...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yu, Jia, Bo, Jiang, Shiyu, Zhou, Shengyu, Yang, Jianliang, Liu, Peng, Gui, Lin, He, Xiaohui, Qin, Yan, Sun, Yan, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217200/
https://www.ncbi.nlm.nih.gov/pubmed/28057019
http://dx.doi.org/10.1186/s13045-016-0368-9
_version_ 1782492060586082304
author Huang, Yu
Jia, Bo
Jiang, Shiyu
Zhou, Shengyu
Yang, Jianliang
Liu, Peng
Gui, Lin
He, Xiaohui
Qin, Yan
Sun, Yan
Shi, Yuankai
author_facet Huang, Yu
Jia, Bo
Jiang, Shiyu
Zhou, Shengyu
Yang, Jianliang
Liu, Peng
Gui, Lin
He, Xiaohui
Qin, Yan
Sun, Yan
Shi, Yuankai
author_sort Huang, Yu
collection PubMed
description The difference in clinical features and treatment outcomes between localized sinonasal diffuse large B cell lymphoma (SN-DLBCL) and sinonasal extranodal NK/T cell lymphoma (SN-ENKTL) is unclear. Therefore, we analyzed a total of 47 patients with localized SN-DLBCL and 211 patients with localized SN-ENKTL. The age distribution for these two subtypes is very distinct and the B symptoms were more common in SN-ENKTL. However, both SN-DLBCL and SN-ENKTL patients could achieve high overall response rate (ORR) and favorable prognoses. The 3-year overall survival (OS) rates for patients with SN-DLBCL and SN-ENKTL were 79.7 and 83.6% (p = 0.707), and the 3-year progression-free survival (PFS) rates were 61.4 and 70.1% (p = 0.294), respectively. For SN-DLBCL patients, chemotherapy followed by involved-field radiotherapy (IFRT) resulted in higher OS (83.7 vs 62.5%) and PFS (63.9 vs 50.0%) compared with chemotherapy alone, but the difference was not significant. No significant difference was found in the OS or PFS between radiotherapy alone and radiotherapy combined with chemotherapy for all patients with SN-ENKTL. But in extensive stage I and stage II SN-ENKTL patients, radiotherapy combined with chemotherapy could significantly improve the PFS (73.8 vs 50.0%) compared with radiotherapy alone. These results indicate that remarkable clinical disparities exist between localized SN-DLBCL and SN-ENKTL. However, different treatment strategies for them can result in similarly favorable prognoses. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0368-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5217200
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52172002017-01-09 Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma Huang, Yu Jia, Bo Jiang, Shiyu Zhou, Shengyu Yang, Jianliang Liu, Peng Gui, Lin He, Xiaohui Qin, Yan Sun, Yan Shi, Yuankai J Hematol Oncol Letter to the Editor The difference in clinical features and treatment outcomes between localized sinonasal diffuse large B cell lymphoma (SN-DLBCL) and sinonasal extranodal NK/T cell lymphoma (SN-ENKTL) is unclear. Therefore, we analyzed a total of 47 patients with localized SN-DLBCL and 211 patients with localized SN-ENKTL. The age distribution for these two subtypes is very distinct and the B symptoms were more common in SN-ENKTL. However, both SN-DLBCL and SN-ENKTL patients could achieve high overall response rate (ORR) and favorable prognoses. The 3-year overall survival (OS) rates for patients with SN-DLBCL and SN-ENKTL were 79.7 and 83.6% (p = 0.707), and the 3-year progression-free survival (PFS) rates were 61.4 and 70.1% (p = 0.294), respectively. For SN-DLBCL patients, chemotherapy followed by involved-field radiotherapy (IFRT) resulted in higher OS (83.7 vs 62.5%) and PFS (63.9 vs 50.0%) compared with chemotherapy alone, but the difference was not significant. No significant difference was found in the OS or PFS between radiotherapy alone and radiotherapy combined with chemotherapy for all patients with SN-ENKTL. But in extensive stage I and stage II SN-ENKTL patients, radiotherapy combined with chemotherapy could significantly improve the PFS (73.8 vs 50.0%) compared with radiotherapy alone. These results indicate that remarkable clinical disparities exist between localized SN-DLBCL and SN-ENKTL. However, different treatment strategies for them can result in similarly favorable prognoses. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0368-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-05 /pmc/articles/PMC5217200/ /pubmed/28057019 http://dx.doi.org/10.1186/s13045-016-0368-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Huang, Yu
Jia, Bo
Jiang, Shiyu
Zhou, Shengyu
Yang, Jianliang
Liu, Peng
Gui, Lin
He, Xiaohui
Qin, Yan
Sun, Yan
Shi, Yuankai
Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma
title Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma
title_full Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma
title_fullStr Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma
title_full_unstemmed Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma
title_short Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma
title_sort different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large b cell lymphoma and extranodal nk/t cell lymphoma
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217200/
https://www.ncbi.nlm.nih.gov/pubmed/28057019
http://dx.doi.org/10.1186/s13045-016-0368-9
work_keys_str_mv AT huangyu differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma
AT jiabo differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma
AT jiangshiyu differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma
AT zhoushengyu differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma
AT yangjianliang differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma
AT liupeng differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma
AT guilin differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma
AT hexiaohui differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma
AT qinyan differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma
AT sunyan differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma
AT shiyuankai differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma